Melanoma is a malignant skin tumor in which progression of the disease occurs most frequently in the first 3 years after removal of the primary tumor, and metastasis can occur at any time and any place. However, early detection of disease progression improves prognosis and patient survival, and tumor markers may help us in this. Serum markers and radiological imaging methods are used in daily practice, but serum markers may be more readily available and more suitable for close monitoring of the disease. However, according to the current melanoma guideline, “there is no consensus on the suitability of blood tests for monitoring the disease”. Our research team performed a meta-analysis study of serum S100B and lactate dehydrogenase (LDH), concluding that S100B is a better biomarker for identifying distant metastasis in terms of diagnostic impact, but both biomarkers were independent and strong prognostic markers. The objective of this study was to determine the diagnostic and prognostic abilities of serum S100B and LDH in our patients with melanoma. In the study we processed data of more than 200 patients with malignant melanoma diagnosed at Department of Dermatology University of Debrecen. Based on the radiological imaging methods at the end of the therapy the outcome of disease was divided into three categories: progressive disease, stable disease and partial or complete response. The investigated biomarkers were serum S100B and LDH. The discriminative ability (Area Under the Curve, sensitivity, specificity, diagnostic accuracy) and overall survival rates were calculated. The results showed that the survival was significantly worse in the group with high S100B and high LDH levels at the start of therapy. According to our results, based on the baseline laboratory parameters, serum S100B and LDH are relevant prognostic markers in patients with metastatic melanoma.

ESDR504 - Serum S100B and LDH biomarkers as potential predictive markers of metastatic melanoma

The scientific meeting of the European Society for Dermatological Research (ESDR) is held yearly, usually in September. With an international attendance of more than 1000 skin scientists from around the globe, the four-day event includes short oral presentations from peer-reviewed abstracts, keynote lectures from international experts, sponsored symposia, satellite programs, educational events as well as an important focus on posters, networking and building collaborations amongst scientists. For more information about this year’s meeting visit our website.